What is urticaria? Anatomical, physiological, and histological considerations and classification

Urticaria and Angioedema

Volumn , Issue , 2004, Pages 1-18

  Sabroe, R A ^a   Greaves, Malcolm W ^b  

^a BARNSLEY DISTRICT GENERAL HOSPITAL   (United Kingdom)

^b SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84983170753     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (80)

1. Lewis T. The blood vessels of the human skin and their responses. London: Shaw and Sons. 1927:47.
2. Kirshenbaum AS, Kessler SW, Golf JP, Metcalfe DD. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991: 146:410-415.
3. Columbo M, Horowitz EM, Botana LM, MacGlashan DW Jr. Bochner BS, Gillis S, Zsebo KM, Galli SJ. Lichtenstein LM. The human recombinant c-kit receptor ligand, rhSCF, induces mediator release from human cutaneous mast cells and enhances 19E-dependent mediator release from both skin mast cells and peripheral blood basophils. J Immunol 1992; 149599-608.
4. Buttner C, Henz BM. Welker P. Sepp NT, Grabbe J. Identification of activating c-kit mutations in adult-, but not in cllildhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior. J Invest Dermatol 1998; III: 1227-1231.
5. Barlow RJ, MacDonald DM, Black AK, Greaves MW. The effects of topical corticosteroids on delayed pressure urticaria. Arch Dermatol Res 1995; 287285-288
6. Lawlor F, Black AK, Mmdoch RD, Greaves MW. Symptomatic dermographism: whealing, mast cells and histamine are decreased in the skin following long-term application of a potent topical corticosteroid. Br J Dermatol 1989; 121 :629-634
7. Guzzo C. Lavker R. Roberts LJ 2nd, Fox K. Schechter N, Lazarus G. Urticaria pigmentosa. Systemic evaluation and successful treatment with topical steroids. Arch Dermatol 199\: 127: 191-196.
8. Lawrence ID, Warner JA, Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM. Purification and characterization of human skin mast cells: evidence for human mast cell heterogeneity. J Immunol 1987; 139:3062-3069.
9. Church MK, el-Lati S, Okayama Y. Biological properties or human skin mast cells. Clin Exp Allergy 199: 21(Suppl 3):1-9
10. Okayama Y, Ono Y, Nakazawa T. Church MK, Mori M. Human skin mast cells produce TNF-alpha by substance P. Int Arch Allergy lmmunol 1998; 117(Suppl 1):48-51.
11. Schwartz LB. Mast cells and their role in urticaria JAm Acad Oermatol 1991; 25: 190-204.
12. Walsh LJ, Trinchieri G. Waldorf HA, Whitaker D. Murphy GF Human dermal mast cells contain and release tumor necrosis factor a, which induces endothelial leukocyte adhesion molecule l. Proc Natl Acad Sci USA 1991: 884 220-4224
13. Bradding P, Feather IH. Howarth PH, Mueller R, Roberts lA, Britten K, Bews lPA, Hunt TC, Okayama Y, Heusser CH, Bullock GR, Church MK, Holgate ST. Interleukin 4 is localized to and released by human mast cells. 1 Exp Med 1992; 176 1381-1386.
14. Moller A. Lippert U, Lessmann D, Kolde G. Hamann K, Welker P. Schadendorf O. Rosenbach T. Luger T. Czarnetzki BM. Human mast cells produce 11-8. 1 lmmunol 1993: 151:3261-3266.
15. Krüger-Krasagakes S, Moller A, Kolde G, Lippert U, Weber M, Henz BM. Production of interleukin-6 by human mast cells and basophilic cells. 1 Invest Dermatol 1996: 106:75-79.
16. Artuc M, Steckelings UM, Hentz BM. Mast cell-fibroblast interactions: human mast cells as a source and inducers of fibroblast and epithelial growth factors. 1 Invest Oermatol 2002; 118:391-395.
17. Bradding P. Roberts lA, Britten KM, Montefort S, Ojukanovic R, Mueller R, Heusser CH, Howarth PH, Holgate ST. lnterleukin-4. -5, and -6 and tumor necrosis factor-a in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am 1 Respir Cell Mol Bioi 1994: 10471-480
18. laffe JS, Raible DG, Post TJ, Wang Y, Glaum MC, Butterfield JH, Schulman ES. Human lung mast cell activation leads to IL-13 mRNA expression and protein release. Am 1 Respir Cell Mol Bioi 1996: 15473-481.
19. Okayama Y, Kobayashi H, Ashman LK. Dobashi K. NakazalVa T. Holgate ST, Church MK. Mori M. Human lung mast cells are enriched in the capacity to produce granulocyte-macrophage colony-stimulating factor in response to IgE-dependent stimulation. Eur J Immunol 1998; 28:708-715.
20. Baghestanian M. Hofbauer R. Kiener HP, Bankl HC, Wimazal F. Willheim M. Scheiner O. Fureder W, Muller MR. Bevec D. Lechner K. Valent P. The c-kit ligand stem cell factor and anti-IgE promote expression of monocyte chemoattractant protein-I in human lung mast cells Blood 1997; 90: 4438-4449.
21. Wodnar-Filipowicz A, Heusser CH, Moroni C, Production of the haemopoietic growth factors GM-CSF and interlcukin-3 by mast cells in response to IgE receptor-mediated activation. Nature 1989: 339: 150-152.
22. Rumsaeng V, Cruikshank WW, Foster B, Prussin C, Kirshenbaum AS, Davis TA, Kornfeld H, Center DM, Metcalfe DD. Human mast cells produce the CD4+ T lymphocyte chemoattractanl factor. lL-16. J Immunol 1997: 159 2904-2910
23. Selvan RS. Buttcrficld JH, Krangel MS Expression of multiple chemokine genes by a human mast cell leukemia. J Bioi Chem 1994; 269: 13893-13898.
24. Boesiger J, Tsai M, Maurer M, Yamaguchi M, Brown LF, Claffey KP, Dvorak HF, Galli SJ. Mast cells can secrete vascular permeability factor/vascular endothelial cell growth factor and exhibit enhanced release after immunoglobulin E-dependent upregulation of FCE receptor I expression. J Exp Med 1998; 188:1135-1145.
25. Majno G, Gilmore V, Leventhal M. On the mechanisms of vascular leakage caused by histamine-type mediators. A microscopic study in vivo. Circulation Research 1967; 21:833-847.
26. Marks R, Greaves MW. Vascular reactions to histamine and compound 48/80 in human skin: suppression by a histamine H2 receptor blocking agent. Br J Clin Pharmacol 1977; 4:367-369.
27. Kaplan AP, Horakova Z, Katz SI. Assessment of tissue Auid histamine levels in patients with urticaria. J Allergy Clin Immunol 1978; 61: 350-354.
28. Greaves MW, Shuster S. Responses of skin blood vessels to bradykinin histamine and 5-hydroxytryptamine. J Physiol 1967; 193: 255-267
29. Cook J, Shuster S. Histamine wheal formation and absorption in man. Br J Pharmacol 1980; 69:579-585.
30. Kavanagh GM, Sabroe RA, Greaves MW, Archer CB The intradermal effects of the H3 receptor agonist R Ci methyl histamine in human skin. Br J Dermatol 1998; 138:622-626
31. Liu C Ma X, Jiang X, Wilson SJ, Hofstra CL, Blevitt J, Pyati J, Li X, Chai W, Carruthers N. Lovenberg TW. Cloning and pharmacological characterization 01' a fourth histamine receptor (H(4)) expressed in bone marrow. Mol Pharmacol 200 I; 59:420-426.
32. Jutel M, Watanabe T, Klunker S, Akdis M, Thomet OAR. Malolepszy J, Zak-Nejmark T, Koga R, Kobayashi T, Blaser K. Akdis CA. Histamine regulates T-cell and antibody responses by differential expression of H1 and H2 receptors. Nature 2001; 413:420-425.
33. Soter NA. Lewis RA, Corey EJ, Austen KF. Local effects of synthetic leukotrienes (LTC4, LTD4, LTE4, and LTB4) in human skin. J Invest Dermatol 1983; 80: 115-119.
34. Hippenstiel S, Krull M. Ikemann A, Risau W, Clauss M, SUttorp N. VEGF induces hyperpermeability by a direct action on endothelial cells. Am J Physiol 1998; 274:L678-L684
35. Iademarco M F, Barks JL, Dean DC. Regulation of vascular cell adhesion molecule-I expression by IL-4 and TNF-tX in cultured endothelial cells. J C1in Invest 1995; 95:264-271.
36. x-dependent alterations in leukocyte kinetics in vivo. Orc Res 1995; 77:879-887.
37. Yao L. Pan J, Setiadi H, Patel KD, McEver RP. Interleukin 4 or oncostatin M induces a prolonged increase in P-selectin mRNA and protein in human endothelial cells. 1996; 184:81-92.
38. Sabroe T, Hartnell A, Jopling LA, Bel S, Ponath PD, Pease JE, Collins PD, Williams TJ. Differential regulation of eosinophil chemokine signaling via CCR3 and non-CCR3 pathways. J Immunol 1999; 162: 2946-2955
39. Beck LA, Dalke S, Leiferman KM, Bickel CA, Hamilton R, Rosen H. Bochner BS, Schleimer RP. Cutaneous injection of RANTES causes eosinophil recruitment. Comparison of nonallergic and allergic human subjects. J Immunol 1997; 159:2962-2972.
40. Hirai H, Tanaka K, Yoshie O, Ogawa K, Kenmotsu K, Takamori Y, Ichimasa M, Sugamura K, Nakamura M, Takano S, Nagata K. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001: 193:255-261.
41. Hogaboam C, Kunkel SL, Strieter RM, Taub DD, Lincoln P, Standiford TJ, Lukacs NW. Novel role of transmembrane SCF for mast cell activation and eotaxin production in mast cell-fibroblast interactions. J Immunol 1998; 160 6166-6171
42. Leonard EJ, Yoshimura T, Tanaka S, Raffeld M. Neutrophil recruitment by intradermally injected neutrophil attractant/activation protein-I. J Invest Dermatol 1991; 96:690-694.
43. Nicod LP. Cytokines: I. Overview. Thorax 1993; 48:660-667.
44. Gascan H, Gauchat J-F, Roncarolo M-G, Yssel H, Spits H, de Vries JE. Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones. J Exp Med 1991: 173:747-750.
45. Punnonen J, Aversa G, Cocks BG, McKenzie ANJ, Menon S. Zurawski G, de Waal Malefyt R, de Vries JE. Interleukin 13 induces interleukin 4-independent IgG4 and TgE synthesis and CD23 expression by human B cells. Proc Nall Acad Sci USA 1993; 90:3730-3734
46. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, Borsatti A, Sozzani S, Allavena P, Gray PA, Mantovani A, Sinigaglia F. Differential expression of chemokine receptors and chemotactic responsiveness of type I T helper cells (This) and Th2s. J Exp Med 1998: 187 129-134.
47. Swain SL Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Jmmunol 1990: 145:3796-3806.
48. Heberden W. Commentaries on the history and cure of diseases. London: Payne, 1802.
49. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepielowski, JC, Zylicz Z. Itch: snatching more than the surface. Q J Med 2003; 96:7-26.
50. Robertson I, Greaves MW. Responses of human skin blood vessels to synthetic histamine analogues and to histamine. Br J Clin Pharmacol 1978: 5:319-322.
51. Schmelz M, Schmidt R, Bickel A, Handwerker HO, TorcbJork HE, Specificreceptors for itch in human skin. J Neurosci 1997; 17:8003-8008.
52. Andrew D, Craig AD. Spinothalamic lamina 1 neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4: 72-77.
53. Sabroe RA, Seed PT, Francis DM, Barr RM, Kobza Black A, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcɛR 1 or anti-lgE autoantibodies. J Am Acad Dermatol 1999; 40:443-450
54. Yosipovitch G, Greaves, MW, Schmelz, M, Itch-new concepts. Lancet 2003; 361 :690-694.
55. Toyoda M, Maruyama T, Morohashi M, Bhawan J. Free eosinophil granules in urticaria. A correlation with the duration of wheals. Am J Dermatopathol 1996; 18:49-57.
56. Elias J, Boss E, Kaplan AP. Studies of the cellular infiltrate of chronic idiopathic urticaria: prominence of T-Iymphocytes, monocytes and mast cells. J Allergy Clin lmmunol 1986; 78:914-918.
57. Natbony SF, Phillips ME, Elias JM, Godfrey HP, Kaplan AP. Histologic studies of chronic idiopathic urticaria. J Allergy C1in Immunol 1983; 71177-183
58. Barlow RJ, Ross EL, Macdonald DM, Kobza-Black A, Greaves MW. Mast cells and T lymphocytes in chronic urticaria. Clin Exp Allergy 1995; 25:317-322
59. Smith CH, Kepley C, Schwartz LB, Lee TH. Mast cell number and phenotype in chronic idiopathic urticaria. J Allergy Clin Immunol 1995; 96:360-364.
60. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy C1in Immunol 2002; 109 694-700.
61. Sabroe RA, Poon E, Orchard GE, Lane D, Francis DM, Barr RM, Black MM, Kobza Black A, Greaves MW. Cutaneous inflammatory cell infiltrate in chronic idiopathic urticaria: comparison of patients with and without anti-FcERl or anti-IgE autoantibodies. J Allergy Clin Immunol 1999; 103: 484-493
62. Rorsman H. Basopenia in urticaria. Acta Allergol 1961: 16:185-215.
63. Greaves MW, Plummer YM, McLaughlan P, Stanworth DR. Serum and cellbound 19E in chronic urticaria. Clin Allergy 1974; 4:265-271.
64. Sabroe RA, Francis DM, Barr RM, Kobza Black A, Greaves MW. AntiFCɛR 1 autoantibodies and basophil histamine releasability in chronic idiopathic urticaria J Allergy Clin Immunol 1998; 102:651-658.
65. Grattan CEH. Basophils in chronic urticaria. J Invest Dermatol Symp Proc 2001; 6:139-140
66. Hoskin SL, Wilson SJ, Sabroe RA. McEuen AR, Grattan CEH, Greaves MW, Kobza Black A, Black MM, Walls AF. Basophil infiltration of wheals in chronic idiopathic urticaria. J Allergy Clin Immunol 2002; 109:A229.
67. Winkelmann RK, Reizner GT. Diffuse dermal neutrophilia in urticaria. Human Pathol 1988; 19:389-393.
68. Peters, MS, Winkelmann RK, Neutrophilic urticaria, Br J Dermatol, 1985; 113:25-30.
69. Toppe E, Haas N, Henz BM, Neutrophilic urticaria: clinical features, histological changes and possible mechanisms, Br J Dermatol 1998; 138:248-253.
70. Gallo R, Sabroe RA, Black AK, Greaves MW, Schnitzler's syndrome: no evidence for autoimmune basis in two patients, Clin Exp Dermatol 2000; 25281-284
71. DeCastro FR, Massouye I, Winkelmann RK, Saurat JH, Urticarial pathology in Schnitzler's syndrome (hyper IgM syndrome), Dermatology 1996; 193:94-99.
72. Barlow RJ, Warburton F, Watson K, Black AK, Greaves MW, Diagnosis and incidence of delayed pressure urticaria in patients with chronic urticaria, J Am Acad Dermatol 1993; 29:954-958.
73. O'Donnell BF, Lawlor F, Simpson J, Morgan M, Greaves MW, The impact of chronic urticaria on quality of life, Br J Dermatol 1997; 136: 197-20l.
74. Poon E, Seed PT, Greaves MW, Kobza Black A. The extent and nature of disability in different urticarial conditions, Br J Dermatol 1999; 140 667-671.
75. Hashiro M, Okumura M, Anxiety, depression, psychosomatic symptoms and autonomic nervous function in patients with chronic urticaria, J Dermatol Sci 1994; 8:129-135.
76. MacQueen G, Marshall J, Perdue M, Siegel S, Bienenstock J, Pavlovian conditioning of rat mucosal mast cells to secrete mast cell protease. Science 1989; 243 83-85
77. Black S. Shift in dose response curve of Prausnitz-Kustner reaction by direct suggestion under hypnosis. Br Med J 1963; 1:990-992.
78. Koblenzer CS. The urticarias. In: Psychocutaneous disease, Orlando: Grune & Stratton, 1997:203.
79. Medansky RS, Handler RM. Dermatopsychosomatics: classification. physiology, and therapeutic approaches. J Am Acad Dermatol 1981: 5: 125-136.
80. Zuberbier T, Greaves MW, Juhlin L, Kobza Black A, Maurer D, Stingl G, Henz BM, Definition, classification, and routine diagnosis of urticaria: a consensus report. J Invest Dermatol Symp Proc 2001; 6: 123-127.